PolypDX™

POLYPDX™ - DIAGNOSTIC FOR PRECANCEROUS ADENOMATOUS POLYPS
MTI's lead product is a unique diagnostic system that can detect colonic adenomatous polyps (the precursor to colorectal cancer) based on a unique "fingerprint" of metabolites from a urine test. Unlike fecal-based tests, MTI's urine-based PolypDx™ detects polyps before they become cancerous.

COMPETITIVE ADVANTAGES

• Early stage detection: MTI's screening test will detect colonic polyps, the precursor to colorectal cancer, with high accuracy.
• High patient compliance: Non-invasive and does not require any dietary restrictions or fecal collections.
• Higher accuracy: Higher accuracy than existing tests with increased sensitivity, reducing false negatives.
• Savings in overall healthcare costs: Earlier detection of colorectal cancer will save lives and reduce treatment costs.
• Cost-effective and high-throughput platform: Expected to be highly cost-effective in comparison to the cost of existing colon cancer screening tests.